Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 163,700 shares, a growth of 17.5% from the April 30th total of 139,300 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is currently 10.6 days. Approximately 0.6% of the company’s stock are short sold.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in shares of Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after buying an additional 7,500 shares during the period. Millennium Management LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at about $31,000. Raymond James Financial Inc. acquired a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth about $37,000. Royal Bank of Canada increased its stake in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after acquiring an additional 59,683 shares during the period. Finally, Scotia Capital Inc. lifted its position in shares of Eupraxia Pharmaceuticals by 11.6% in the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock worth $5,072,000 after acquiring an additional 160,960 shares during the period.

Eupraxia Pharmaceuticals Stock Down 0.8%

Shares of EPRX opened at $3.94 on Friday. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $4.48. The company’s fifty day moving average is $3.64 and its 200-day moving average is $3.47. The firm has a market cap of $141.25 million, a price-to-earnings ratio of -5.47 and a beta of 0.66.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, research analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They issued a “buy” rating and a $12.00 price objective on the stock.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.